Author
Listed:
- Michela Milani
(San Raffaele Telethon Institute for Gene Therapy, IRCCS San Raffaele Scientific Institute)
- Cesare Canepari
(San Raffaele Telethon Institute for Gene Therapy, IRCCS San Raffaele Scientific Institute
Vita-Salute San Raffaele University)
- Tongyao Liu
(Sanofi)
- Mauro Biffi
(San Raffaele Telethon Institute for Gene Therapy, IRCCS San Raffaele Scientific Institute)
- Fabio Russo
(San Raffaele Telethon Institute for Gene Therapy, IRCCS San Raffaele Scientific Institute)
- Tiziana Plati
(San Raffaele Telethon Institute for Gene Therapy, IRCCS San Raffaele Scientific Institute)
- Rosalia Curto
(San Raffaele Telethon Institute for Gene Therapy, IRCCS San Raffaele Scientific Institute)
- Susannah Patarroyo-White
(Sanofi)
- Douglas Drager
(Sanofi)
- Ilaria Visigalli
(San Raffaele Telethon Institute for Gene Therapy, IRCCS San Raffaele Scientific Institute)
- Chiara Brombin
(University Center for Statistics in the Biomedical Sciences, Vita-Salute San Raffaele University)
- Paola Albertini
(San Raffaele Telethon Institute for Gene Therapy, IRCCS San Raffaele Scientific Institute)
- Antonia Follenzi
(University of Piemonte Orientale)
- Eduard Ayuso
(INSERM UMR1089, University of Nantes, CHU de Nantes)
- Christian Mueller
(Sanofi)
- Andrea Annoni
(San Raffaele Telethon Institute for Gene Therapy, IRCCS San Raffaele Scientific Institute)
- Luigi Naldini
(San Raffaele Telethon Institute for Gene Therapy, IRCCS San Raffaele Scientific Institute
Vita-Salute San Raffaele University)
- Alessio Cantore
(San Raffaele Telethon Institute for Gene Therapy, IRCCS San Raffaele Scientific Institute
Vita-Salute San Raffaele University)
Abstract
Liver gene therapy with adeno-associated viral (AAV) vectors delivering clotting factor transgenes into hepatocytes has shown multiyear therapeutic benefit in adults with hemophilia. However, the mostly episomal nature of AAV vectors challenges their application to young pediatric patients. We developed lentiviral vectors, which integrate in the host cell genome, that achieve efficient liver gene transfer in mice, dogs and non-human primates, by intravenous delivery. Here we first compare engineered coagulation factor VIII transgenes and show that codon-usage optimization improved expression 10-20-fold in hemophilia A mice and that inclusion of an unstructured XTEN peptide, known to increase the half-life of the payload protein, provided an additional >10-fold increase in overall factor VIII output in mice and non-human primates. Stable nearly life-long normal and above-normal factor VIII activity was achieved in hemophilia A mouse models. Overall, we show long-term factor VIII activity and restoration of hemostasis, by lentiviral gene therapy to hemophilia A mice and normal-range factor VIII activity in non-human primate, paving the way for potential clinical application.
Suggested Citation
Michela Milani & Cesare Canepari & Tongyao Liu & Mauro Biffi & Fabio Russo & Tiziana Plati & Rosalia Curto & Susannah Patarroyo-White & Douglas Drager & Ilaria Visigalli & Chiara Brombin & Paola Alber, 2022.
"Liver-directed lentiviral gene therapy corrects hemophilia A mice and achieves normal-range factor VIII activity in non-human primates,"
Nature Communications, Nature, vol. 13(1), pages 1-14, December.
Handle:
RePEc:nat:natcom:v:13:y:2022:i:1:d:10.1038_s41467-022-30102-3
DOI: 10.1038/s41467-022-30102-3
Download full text from publisher
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:13:y:2022:i:1:d:10.1038_s41467-022-30102-3. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
We have no bibliographic references for this item. You can help adding them by using this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.